Standout Papers

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme 2006 2026 2012 2019 1.0k
  1. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme (2007)
    James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology
  2. Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells (2009)
    Zhizhong Li, Shideng Bao et al. Cancer Cell
  3. Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor (2006)
    Shideng Bao, Qiulian Wu et al. Cancer Research
  4. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma (2007)
    James J. Vredenburgh, Annick Desjardins et al. Clinical Cancer Research

Immediate Impact

12 by Nobel laureates 31 from Science/Nature 134 standout
Sub-graph 1 of 17

Citing Papers

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
2023 Standout
What is cancer metabolism?
2023 Standout

Works of Sith Sathornsumetee being referenced

Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation
2021
Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells
2009 Standout

Author Peers

Author Last Decade Papers Cites
Sith Sathornsumetee 4044 1224 2202 3354 2502 89 7.3k
Ryo Nishikawa 4172 1648 2071 3205 1874 198 8.3k
Daniel P. Cahill 4070 1429 2430 4201 2437 173 9.5k
Katrin Lamszus 2474 952 2140 3734 2103 150 7.7k
Ken Aldape 3609 951 1193 3849 2095 60 7.3k
Jennifer A. Quinn 3802 1426 1209 2304 1416 77 5.9k
V. Peter Collins 3150 1116 2356 3864 2107 77 7.6k
Marie‐France Hamou 5164 1766 1799 4080 2625 46 8.9k
Do‐Hyun Nam 2137 788 2329 3588 2196 143 6.9k
W.K. Alfred Yung 3034 1415 1349 2894 1233 107 5.8k
D. Williams Parsons 4557 1283 1901 5195 3246 91 9.9k

All Works

Loading papers...

Rankless by CCL
2026